Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
2(10%)
Results Posted
13%(2 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_4
4
19%
Ph not_applicable
4
19%
Ph phase_1
3
14%
Ph phase_2
4
19%
Ph phase_3
5
24%

Phase Distribution

3

Early Stage

4

Mid Stage

9

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
3(15.0%)
Phase 2Efficacy & side effects
4(20.0%)
Phase 3Large-scale testing
5(25.0%)
Phase 4Post-market surveillance
4(20.0%)
N/ANon-phased studies
4(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

21

all time

Status Distribution
Active(2)
Completed(15)
Terminated(1)
Other(3)

Detailed Status

Completed15
unknown3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
2
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (15.0%)
Phase 24 (20.0%)
Phase 35 (25.0%)
Phase 44 (20.0%)
N/A4 (20.0%)

Trials by Status

completed1571%
terminated15%
recruiting210%
unknown314%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT02939573Phase 2

A Randomized Multicenter Study for Isolated Skin Vasculitis

Recruiting
NCT05984381Phase 4

Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid

Completed
NCT06819449Not Applicable

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

Recruiting
NCT05131295Phase 3

Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.

Completed
NCT00000991Phase 3

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

Completed
NCT00000802Phase 3

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

Completed
NCT00000739Phase 1

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Completed
NCT00000640Phase 3

A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS

Completed
NCT00001028Phase 3

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

Completed
NCT00000826Phase 1

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites

Completed
NCT00162383Not Applicable

Metabolic Capacity of Israeli Populations

Unknown
NCT00993694

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Completed
NCT02550080Phase 4

Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

Unknown
NCT01165840Phase 4

Effect of Weight and/or Obesity on Dapsone Drug Concentrations

Completed
NCT00000596Phase 2

Diffuse Fibrotic Lung Disease

Completed
NCT00834210Phase 4

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

Completed
NCT01144650Phase 2

Dapsone for Acute Ischemia Stroke Study

Unknown
NCT00429533Phase 2

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

Terminated
NCT00002043Not Applicable

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Completed
NCT00002283Not Applicable

A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Completed

Drug Details

Intervention Type
DRUG
Total Trials
21